We are developing a robust clinical pipeline of chimeric antigen receptor (CAR) and T cell receptor (TCR) products.
Our most advanced candidate, axicabtagene ciloleucel (formerly known as KTE-C19), has been submitted to the U.S. Food and Drug Administration for approval as a treatment for patients with relapsed or refractory aggressive non-Hodgkin lymphoma (NHL) who are ineligible for autologous stem cell transplant. Additional indications are being pursued for the full KTE-C19 development program.
We are also advancing our first TCR product candidate, KITE-718, in a company-sponsored clinical trial.
Learn more about our ongoing clinical trials at www.clinicaltrials.gov.
Kite Pharma Expanded Access Policy
Treating physicians may request information about Expanded Access for a Kite Pharma therapy by contacting Kite Medical Information at 1-844-454-KITE.
Kite will evaluate these requests individually. Kite may provide physician requested Expanded Access for a Kite therapy for patients with no other available therapies and for patients who are not eligible to participate in a current Kite clinical trial. Kite will acknowledge receipt of the request via telephone call or email within 5 business days of receipt of the request.
Information on all Kite trials can be found on ClinicalTrials.gov.
Pursuant to the 21st Century Cures Act: the posting of policies by manufacturers and distributors shall not serve as a guarantee of access to any specific investigational therapy by any individual patient.
axicabtagene ciloleucel DLBCL, PMBCL & TFL (ZUMA-1)
KTE-C19 (WAVE-1) MCL (ZUMA-2)
KTE-C19 (WAVE-1) Adult & Pediatric ALL (ZUMA-3 & ZUMA-4)
KTE-C19 (WAVE-2) Indolent NHL (ZUMA-5)
KTE-C19 (WAVE-2) DLBCL (PD-L1 mAb) (ZUMA-6)
KTE-C19 (WAVE-2) DLBCL (2nd line) (ZUMA-7)
KTE-C19 (WAVE-2) CLL (ZUMA-8)
Human Anti-CD19 (2nd generation) Heme malignancies (NCI)
Humanized anti-CD19 control CAR (3rd generation) Heme malignancies
KITE-585 (anti-BCMA) MM
KITE-796 (anti-CLL-1 control CAR) AML
MAGE A3/A6 Solid tumor (NCI)
KITE-718 (MAGE A3/A6) Solid tumor
MAGE A3 Solid tumor (NCI)
HPV-16 E6 & E7 Cervical and head & neck cancer (NCI)
KITE-439 (HPV-16 E7) Cervical and head & neck cancer
SSX-2 Solid tumor (NCI)
KRAS Solid tumor (NCI)
Neoantigens Solid tumor (NCI)
Medical Information, Clinical Trials & Product Complaints
firstname.lastname@example.org (844) 454-KITE